Key Points – Amgen said its strong first-quarter results support the idea that 2026 could be a “springboard year”, with revenue up 6% and EPS up 5% as growth products offset patent and exclusivity pressure on older drugs. – The company highlighted several major growth drivers —…
cluding Repatha, EVENITY, TEZSPIRE, oncology, rare disease and biosimilars — which together made up about 70% of first-quarter product sales and grew 24% year over year. – Amgen is also leaning on its pipeline, especially MariTide for obesity and diabetes, plus late-stage programs like olpasiran and xaluritamig, while continuing to expand UPLIZNA and other rare-disease launches. – Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity
Speaking at a Goldman Sachs event, Peter Griffith, Amgen’s chief financial officer, said first-quarter revenue rose 6% year-over-year and non-GAAP earnings per share increased 5%. He said 16 products delivered double-digit or better sales growth, while 17 products were annualizing at more than $1 billion in product sales based on first-quarter results. – 3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most Griffith said six key growth drivers — Repatha, EVENITY, TEZSPIRE, the company’s innovative oncology portfolio, rare disease portfolio and biosimilars portfolio — accounted for about 70% of product sales in the first quarter and grew 24% as a group year-over-year. Executives Point to Breadth of Growth Drivers Murdo Gordon, head of global commercial operations, said Amgen has a “set of prioritized growth drivers” that he believes can help the company manage the impact of current and future losses of exclusivity, including denosumab and Otezla in Europe. – 5 Healthcare Names to Watch…